DelveInsight’s Choroideremia pipeline report provides comprehensive insights into the Choroideremia market’s current clinical development scenario and growth prospects. The report provides a detailed description of the drug, including the drug’s mechanism of action, clinical studies, NDA approvals, and product development activities involving the technology.
Key Takeaways from the Choroideremia Pipeline Report
The Choroideremia pipeline comprises emerging therapies in the different clinical stages, including BIIB111, SPK-7001, 4D-110, Metformin, and others.
Key companies working to improve the Choroideremia treatment landscape include NightstaRx Ltd, Spark Therapeutics, 4D Molecular Therapeutics, Curative Biotech, among others.
The Choroideremia pipeline therapies in the late stages of development include BIIB111 (NightstaRx Ltd), SPK-7001 (Spark Therapeutics), and others.
4D-110 is being developed and investigated in the phase I Choroideremia clinical trials by 4D Molecular Therapeutics.
Metformin (Curative Biotech) is still in the early phase of development, i.e., preclinical stage for Choroideremia.
Request for the sample to know more about the choroideremia pipeline @ Choroideremia Pipeline Therapies Analysis
Choroideremia Overview
Choroideremia is a rare genetic vision disorder that affects more men than women. It is an X-linked recessive condition that causes the choroid, retinal pigment epithelium (RPE), and photoreceptors to degrade gradually. Females are the majority of carriers and are mostly unaffected, though they may experience minor symptoms such as blurred vision later in life.
Choroideremia Symptoms
The disease usually manifests itself in childhood, around the age of five or six. The child develops night blindness, or the inability to see objects in dim lighting, followed by loss of peripheral vision due to choroid blood vessel degeneration. Loss of color vision as a result of macula degeneration is another common symptom.
Choroideremia Treatment
Choroideremia currently has no treatment or cure. However, depending on the intensity of the symptoms, the patient may be offered symptom-specific treatment. However, because Choroideremia is a genetic condition, gene therapy and small molecule medications may be viable treatment choices for Choroideremia patients.
Choroideremia Pipeline Analysis: Drug Profiles
BIIB111: NightstaRx Ltd
Product Description
NightstaRx Ltd developed BIIB111 for the treatment of Choroideremia. BIIB111 is a gene therapy treatment consisting of an AAV2 vector with recombinant human DNA meant to deliver REP1 protein to the retina.
Phase III
NCT03496012: NightstaRx Ltd. began a Phase III trial of retinal gene therapy for Choroideremia using an Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1) in December 2017.
Choroideremia Pipeline Therapies and Key Companies
SPK-7001: Spark Therapeutics
4D-110: 4D Molecular Therapeutics
Metformin: Curative Biotech
Find out more about the emerging drugs @ Choroideremia Emerging Therapies and Companies
Choroideremia Therapeutics Assessment
By Product Type
Monotherapy
Combination Therapy
By Stage
Discovery
Pre-Clinical
Phase I
Phase II
Pre-registration
By Route of Administration
Inhalation
Intravenous
Oral
Subcutaneous
By Molecule Type
Small Molecule
Stem Cell Therapy
Gene Therapy
Targets
Immune System
Multiple Kinase
By Mechanism of Action
Protease Inhibitors
Immunomodulatory
Scope of the Report
Coverage: Global
Choroideremia Key Players: NightstaRx Ltd, Spark Therapeutics, 4D Molecular Therapeutics, Curative Biotech, among others
Choroideremia Pipeline Therapies: BIIB111, SPK-7001, 4D-110, Metformin, and others
Table of Contents
1.
Introduction
2.
Executive Summary
3.
Choroideremia: Overview
4.
Choroideremia Analytical Perspective In-depth Commercial Assessment
5.
Choroideremia Pipeline Therapeutics
6.
Choroideremia Late Stage Products (Phase III)
7.
Choroideremia Mid Stage Products (Phase II)
8.
Choroideremia Early Stage Products (Phase I & I/II)
9.
Choroideremia Preclinical Products
10.
Choroideremia Therapeutic Assessment
11.
Choroideremia Inactive Products
12.
Choroideremia Company-University Collaborations (Licensing/Partnering) Analysis
13.
Choroideremia Key Companies
14.
Choroideremia Key Products
15.
Choroideremia Unmet Needs
16.
Choroideremia Market Drivers and Barriers
17.
Choroideremia Future Perspectives and Conclusion
18.
Choroideremia Analyst Views
19.
Appendix
20.
About DelveInsight
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts
Key questions answered in the Choroideremia Pipeline Report
What are the therapy options for Choroideremia?
How many pharmaceutical companies are working on therapies for Choroideremia?
Which of these firms’ medications are the most popular?
What is the total number of Choroideremia drugs produced by each company?
How many Choroideremia medicines are currently in the early, mid, or late stages of development?
How many of the therapies now in development can be used alone or in conjunction with others?
What are the most crucial industry-industry and industry-academy cooperation, mergers and acquisitions, and licensing strategies that impact Choroideremia?
Related Reports
Choroidal Neovascularization Pipeline Insights
“Choroidal Neovascularization Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Choroidal Neovascularization market.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/